drugset / Trial / NCT01361711
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Phase 2
Active not recruiting
53 enrolled
Northwestern University
GlaxoSmithKline · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Giving alemtuzumab together with ofatumumab may kill more cancer cells
Timeline
- Start
- 2011-06
- Primary completion
- 2015-08-17
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Ofatumumab | Monoclonal antibody | — | — |